Corpus ID: 19977079

Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.

  title={Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.},
  author={Charles E. Miller and E. Zbella and B. Webster and K. Doody and M. Bush and M. Collins},
  journal={The Journal of reproductive medicine},
  volume={58 3-4},
OBJECTIVE To explore the comparative efficacy, safety, and tolerability of agents used for ovarian stimulation and luteal support when applied in a population of women undergoing in vitro fertilization (IVF) using a gonadotropin-releasing hormone (GnRH) antagonist protocol. STUDY DESIGN A phase 4, multicenter, randomized, open-label, exploratory clinical trial was performed at 7 assisted reproductive technology centers in the United States. Subjects included 173 women aged 18-42 years with a… Expand
Luteal phase support for assisted reproduction cycles.
The relative effectiveness and safety of methods of luteal phase support provided to subfertile women undergoing assisted reproduction using progesterone, hCG or GnRH agonist supplementation in ART cycles was determined. Expand
A Review of Luteal Support Protocols for Single Embryo Transfers: Fresh and Frozen
Current data suggest no difference in outcome between hormonally medicated protocols or natural cycles and that no benefit is gained by adding progesterone to the luteal phase of modified natural treatment cycles, so additional research is needed to inform the decision-making process. Expand
Timing luteal support in assisted reproductive technology: a systematic review.
There appears to be a window for P start time between the evening of oocyte retrieval and day 3 after oocytes retrieval, and although some studies have suggested a potential benefit in delaying vaginal P startTime to 2 days after oocyte retrieved, this review could not find randomized controlled trials to adequately assess this. Expand
Luteal phase support for in vitro fertilization/intracytoplasmic sperm injection fresh cycles: a systematic review and network meta-analysis
Delays in progesterone supplementation until 96 h after oocyte retrieval does not affect pregnancy outcomes and with comparable efficacy and acceptability, there may be several viable clinical options for LPS. Expand
Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial.
OBJECTIVE To assess the noninferiority of vaginal P (Endometrin) compared with daily intramuscular P for replacement in programmed vitrified-warmed blastocyst transfer cycles and to assess theExpand
Smoking Decreases Endometrial Thickness in IVF/ICSI Patients
It is shown that smoking has a negative effect on endometrial thickness on the day of embryo transfer, which may help to further explain the detrimental influence of tobacco smoke on implantation and pregnancy rates during assisted reproduction therapy. Expand
A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest®) for luteal phase support during IVF treatment
Overall patient convenience, ease, and comfort with using progesterone vaginal tablets for LPS is suggested, with the majority of patients found progesterOne vaginal tablets more convenient and comfortable to use compared with progester one pessaries. Expand
S Svjetska zdravstvena organizacija je definirala neplodnost kao izostanak trudnoce nakon 12 mjeseci redo. Expand
Kontrola menstruacijskog ciklusa za medicinski potpomognutu oplodnju
Neplodnost kao jedan od vodecih javnozdravstvenih problema se definira kao izostanak trudnoce nakon jedne godine nastojanja u zajednickom životu.